Moraski, Garrett C.Cheng, YongCho, SanghyunCramer, Jeffrey WGodfrey, AlexanderMasquelin, ThierryFranzblau, Scott G.Miller, Marvin J.Schorey, Jeffery2017-02-142017-02-142016-08Moraski, Garrett C, Yong Cheng, Sanghyun Cho, Jeffrey W Cramer, Alexander Godfrey, Thierry Masquelin, Scott G Franzblau, Marvin J Miller, and Jeffery Schorey. "Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo.." Antimicrobial Agents and Chemotherapy 60, no. 8 (August 2016): 5018-5022. DOI:https://dx.doi.org/10.1128/AAC.00618-16.1098-6596https://scholarworks.montana.edu/handle/1/12605A panel of six imidazo[1,2-a]pyridine-3-carboxamides (IAPs) were shown to have low-micromolar activity against Mycobacterium avium strains. Compound ND-10885 (compound 2) showed significant activity in the lung, spleen, and liver in a mouse M. avium infection model. A combined regimen consisting of ND-10885 (compound 2) and rifampin was additive in its anti-M. avium activity in the lung. Our data indicate that IAPs represent a new class of antibiotics that are active against M. avium and could potentially serve as an effective addition to a combined treatment regimen.en-USArticle